All Blogs
Jan 30, 2025
Norlase’s LYNX Receives FDA and CE Approval for Clinical Use; FDA Approves Imperative Care’s Zoom System; Lunit AI Enhances Predictive Accuracy for HER2-Targeted Therapy in Metastatic Colorectal Cancer; ImmunoMet Reports New Insights from Phase 1b Study of Lixumistat in Pancreatic Cancer; Lumicell Announces U.S. Launch of LumiSystem; Inventia Life Science Introduces RASTRUM™ Allegro to Advance High-Throughput 3D Cell Culture
Norlase Received FDA 510(k) Clearance and CE Mark for LYNX™ Indirect Laser Ophthalmoscope with Pattern Tracking On January 27, 2025, Norlase, a leading global manufacturer of ophthalmic lasers developing next-generation laser solutions, announced the commercial launch and receipt of FDA 510(k) clearance and CE M...
Read More...
Jan 29, 2025
Microbial Fermentation Technology: Revolutionizing Biotechnology and Industry
Microbial fermentation technology is a cornerstone of modern biotechnology, playing a vital role in various industries, from pharmaceuticals and agriculture to food production and environmental sustainability. By leveraging the natural metabolic processes of microorganisms, fermentation has evolved into a powerful ...
Read More...
Jan 28, 2025
FDA Approves LEQEMBI IV Dosing for Early Alzheimer’s; Vanda Accepts FDA Hearing on Tradipitant for Gastroparesis; Cartesian Gains FDA Protocol Approval for Myasthenia Gravis Trial; Zai Lab Secures FDA Orphan Status for DLL3 ADC in SCLC; Dyne Receives FDA Fast Track for DYNE-101 in Myotonic Dystrophy
FDA Approves LEQEMBI® (Lecanemab-Irmb) IV Maintenance Dosing for Early Alzheimer’s Disease Treatment Eisai Co., Ltd. and Biogen Inc. announced that the FDA has approved the Supplemental Biologics License Application (sBLA) for LEQEMBI (lecanemab-irmb), allowing intravenous (IV) maintenance dosing every four week...
Read More...
Sep 22, 2025
The Future of Multiple System Atrophy Treatment: Pioneering Approaches Beyond Levodopa Reliance
Multiple system atrophy (MSA) is a rare and progressive neurodegenerative disorder that affects the autonomic nervous system, motor function, and balance. Multiple system atrophy symptoms manifests through a combination of parkinsonism, autonomic dysfunction, and cerebellar ataxia, making it distinct from Parkinson...
Read More...
Jan 24, 2025
Gene Therapies at J.P. Morgan 2025: Advancing Science and Shaping the Future
The 43rd Annual J.P. Morgan Healthcare Conference in 2025 showcased the accelerating progress of cell and gene therapies, reaffirming their transformative potential in modern medicine. Despite prior challenges, the field is now demonstrating tangible success, heralding a new era in treating complex and previously u...
Read More...
Jan 24, 2025
Pharma & Biotech Reshaped: Key Mergers and Acquisitions from J.P. Morgan 2025
The 2025 J.P. Morgan Healthcare Conference ignited a new era of M&A activity, marking the industry’s largest consolidation wave in recent years. The M&A rebound in the healthcare sector has been years in the making, as pharma giants like J&J, GSK, and others face looming patent cliffs, threaten...
Read More...
Jan 24, 2025
Graves’ Disease Drug Pipeline: 6 Late-Stage Therapies to Watch
The pipeline for Graves’ disease drug treatments is rapidly expanding, with prominent companies such as Immunovant, Viridian Therapeutics, Argenx, Tourmaline Bio, Hoffmann-La Roche, and Sling Therapeutics spearheading the development of targeted therapies for thyroid disorders. Promising candidates in the late stag...
Read More...
Jan 23, 2025
Tempus Launches FDA-Approved xT CDx Test Nationwide; B. Braun Enhances Catheter Securement with the Launch of Clik-FIX; Illuccix® Secures European Regulatory Approval; FDA Clears CapsoCam Plus® for Remote Ingestion; BellaSeno Marks Success in Two Clinical Trials for Revolutionary Breast Implant Technology; AF Symposium to Feature Conformal Medical’s Groundbreaking GLACE Study
Tempus Announced the National Launch of the FDA-Approved xT CDx Test On January 15, 2025, Tempus AI, Inc., a technology company driving the use of AI to advance precision medicine and improve patient care, announced the nationwide launch of its FDA-approved, NGS-based in vitro diagnostic device, xT CDx. Th...
Read More...
Jan 22, 2025
8 Game-Changing Applications of Healthcare Mobility Solutions
In today’s fast-paced world, healthcare mobility solutions are transforming the way care is delivered, making it smarter, faster, and more accessible than ever. From real-time patient monitoring and seamless teleconsultations to efficient appointment management and medication tracking, these solutions are bridging ...
Read More...
Jan 21, 2025
FDA Approves LUMAKRAS with VECTIBIX for KRAS G12C-Mutated Colorectal Cancer; PYC Receives FDA Rare Pediatric Disease Designation for VP-001; Novo Nordisk Links High-Dose WEGOVY to Increased Weight Loss; FDA Rejects Atara’s EBVALLO Due to Manufacturing Issues; Boehringer Faces Phase III Schizophrenia Fail and Legal Challenges
FDA Approves LUMAKRAS and VECTIBIX for KRAS G12C-Mutated Colorectal Cancer Amgen has secured FDA approval for LUMAKRAS (sotorasib) in combination with VECTIBIX (panitumumab) as a treatment for adults with KRAS G12C-mutated metastatic colorectal cancer (mCRC) who have previously received fluoropyrimidine-, oxalip...
Read More...